Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: A single-arm cohort study

Health Technology Assessment

Volumn 17, Issue 11, 2013, Pages 1-98

  Duffy, S W ^a   Mackay, J ^b   Thomas, S ^c   Anderson, E ^d   Chen, T H H ^e   Ellis, I ^f   Evans, G ^g   Fielder, H ^c   Fox, R ^c   Gui, G ^h   Macmillan, D ⁱ   Moss, S ^a   Rogers, C ^c   Sibbering, M ^j   Wallis, M ^k   Warren, R ^k   Watson, E ^l   Whynes, D ^f   Allgood, P ^a   Caunt, J ^m  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PUBLIC HEALTH WALES   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^j ROYAL DERBY HOSPITAL   (United Kingdom)

^k ADDENBROOKE S HOSPITAL   (United Kingdom)

^l OXFORD BROOKES UNIVERSITY   (United Kingdom)

^m Breast Test Wales   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HEALTH CARE QUALITY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OVARY CANCER; RISK REDUCTION; TUMOR VOLUME; UNITED KINGDOM;

ADULT; BREAST NEOPLASMS; COHORT STUDIES; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; OVARIAN NEOPLASMS; POPULATION SURVEILLANCE; PREVALENCE; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE;

EID: 84875406857     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17110     Document Type: Article

References (91)

1. NHS Cancer Screening Programmes. Breast and cervical screening: the first 20 years. Sheffield: NHSCSP; 2008.
2. Hendrick RE, Smith RA, Rutledge JH III, Smart CR. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monographs 1997;22:87-92.
3. Fletcher SW. Breast cancer screening among women in their forties: an overview of the issues. J Natl Cancer Inst Monographs 1997;22:5-9.
4. Organising committee and collaborators. Breast-cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996;68:693-9. http://dx.doi.org/10.1002/ (SICI)1097-0215(19961211)68:6(693::AID-IJC163.0.CO;2-Z
5. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71. http:// dx.doi.org/10.1126/science.7545954
6. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92. http://dx.doi.org/10.1038/378789a0
7. Evans DG, Lalloo F. Risk assessment and management of high risk familial breast cancer. J Med Genet 2002;39:865-71. http://dx.doi.org/10.1136/jmg.39.12.865
8. Eccles DM, Evans DGR, Mackay J, UK Cancer Family Study Group. Guidelines for a genetic risk based approach to advising women with family history of breast cancer. J Med Genet 2000;37:203-9. http://dx.doi.org/10.1136/jmg.37.3.203
9. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78. http://dx.doi. org/10.1016/S0140-6736(05)66481-1
10. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37. http://dx.doi.org/10.1056/NEJMoa031759
11. Salhab M, Bismohun S, Mokbel K. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Women's Health 2010;10:28. http://dx.doi. org/10.1186/1472-6874-10-28
12. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-6. http://dx.doi.org/10.1200/JCO.2004.00.7138
13. Macmillan RD. Screening women with a family history of breast cancer-results from the British Familial Breast Cancer Group. Eur J Surg Oncol 2000;26:149-52. http://dx.doi.org/10.1053/ ejso.1999.0759
14. Mackay J, Rogers C, Fielder H, Blamey R, Macmillan D, Boggis C, et al. Development of a protocol for evaluation of mammographic surveillance services in women under 50 with a family history of breast cancer. J Epidemiol Biostat 2001;6:365-9. http://dx.doi.org/10.1080/135952201753337086
15. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. AM J Hum Genet 1991;48:232-42.
16. Decarli A, Calza S, Masala G. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Investigation into Cancer and Nutrition cohort. J Natl Cancer Inst 2006;98:1686-93. http://dx.doi.org/10.1093/jnci/djj463
17. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30. http://dx.doi.org/10.1002/sim.1668
18. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH. The randomized trials of breast cancer screening: what have we learned? Radiol Clin N Amer 2004;42:793-806. http://dx.doi. org/10.1016/j.rcl.2004.06.014
19. Wald NJ, Chamberlain J, Hackshaw A. European Society of Mastology Consensus Conference on breast cancer screening: report of the evaluation committee. Br J Radiol 1994;67:925-33. http:// dx.doi.org/10.1259/0007-1285-67-802-925
20. FH01 management committee, steering committee and collaborators. The challenge of evaluating annual mammography screening for young women with a family history of breast cancer. J Med Screening 2006;13:177-82.
21. Tabár L, Duffy SW, Chen HH. Re: Quantitative interpretation of age-specific mortality reductions from the Swedish Breast Cancer-Screening Trials. J Natl Cancer Inst 1996;88:52-5. http://dx.doi. org/10.1093/jnci/88.1.52-a
22. Moss S, Waller M, Anderson TJ, Cuckle H. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer 2005;92:955-60. http://dx.doi.org/10.1038/sj.bjc.6602395
23. FH01 Collaborative Groups. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. Lancet Oncol 2010;11:1127-34. http://dx.doi. org/10.1016/S1470-2045(10)70263-1
24. Bjurstam N, Björneld L, Warwick J, Sala E, Duffy SW, Nyström L, et al. The Gothenburg Breast Screening Trial. Cancer 2003;97:2387-96. http://dx.doi.org/10.1002/cncr.11361
25. Brekelmans CTM, Tilanus-Linthorst MMA, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BCRA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43:867-76. http://dx.doi.org/10.1016/j.ejca.2006.12.009
26. Blamey RW. The British Association of Surgical Oncology guidelines for surgeons in the management of symptomatic breast disease in the UK. Eur J Surg Oncol 1998;24:464-76. http:// dx.doi.org/10.1016/S0748-7983(98)93104-3
27. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish Two-County program of mammographic screening for breast cancer. Radiol Clin N Amer 1992;30:187-210.
28. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-99. Eur J Cancer 2007;43:1548-55 http://dx.doi.org/10.1016/j.ejca.2007.01.016
29. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-14. http://dx.doi.org/10.1136/jmg.40.11.807
30. Casella G, Berger RL. Statistical inference. Belmont, CA: Duxbury Press; 2002.
31. Tyndel S, Clements A, Bankhead C, Henderson BJ, Brain K, Watson E, et al. Mammographic screening for young women with a family history of breast cancer: knowledge and views of those at risk. Br J Cancer 2008;99:1007-12. http://dx.doi.org/10.1038/sj.bjc.6604672
32. Brain K, Henderson BJ, Tyndel S, Bankhead C, Watson E, Clements A, et al. Predictors of breast cancer-related distress following mammography screening in younger women on a family history breast screening programme. Psychooncol 2008;17:1180-8. http://dx.doi.org/10.1002/pon.1355
33. Tyndel S, Austoker J, Henderson BJ, Brain K, Bankhead C, Clements A, et al. What is the psychological impact of mammographic screening on younger women with a family history of breast cancer? Findings from a prospective cohort study by the PIMMS Management Group. J Clin Oncol 2007;25:3823-30. http://dx.doi.org/10.1200/JCO.2007.11.0437
34. Henderson BJ, Tyndel S, Brain K, Clements A, Bankhead C, Austoker J, et al. Factors associated with breast cancer-specific distress in younger women participating in a family history mammography screening programme. Psychooncol 2008;17:74-82. http://dx.doi.org/10.1002/pon.1201
35. NHS Cancer Screening Programmes. NHS Breast Screening Programme annual review 2010. Sheffield: NHSBSP; 2010.
36. National Quality Assurance Co-ordinating Group for Radiography. Quality assurance guidelines for mammography including radiographic quality control. Sheffield: NHS Cancer Screening Programmes; 2006.
37. Young KC. Radiation doses in the UK trial of breast screening in women aged 40-48 years. Br J Radiol 2002;75:362-70.
38. Day NE, Walter SD. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics 1984;40:1-14. http://dx.doi.org/10.2307/2530739
39. Britton P, Warwick J, Wallis MG, O'Keeffe S, Taylor K, Sinnatamby R, et al. Measuring the accuracy of diagnostic imaging in symptomatic breast patients: team and individual performance. Br J Radiol 2012;85:415-22. http://dx.doi.org/10.1259/bjr/32906819
40. Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer 2011;47:2517-
41. http://dx.doi.org/10.1016/j.ejca.2011.06.019
42. Department of Health (DoH). National schedule of reference costs 2010-11 for NHS trusts and PCTs combined, dh_131148. London: DoH; 2011.
43. Guerriero C, Gillan MGC, Cairns J, Wallis MG, Gilbert FJ. Is computer-aided detection cost-effective in screening mammography? A model based on the CADET 2 study. BMC Health Services Res 2011;11:11. http://dx.doi.org/10.1186/1472-6963-11-11
44. Madan J, Rawdin A, Stevenson M, Tappenden P. A rapid-response economic evaluation of the UK NHS cancer reform strategy breast cancer screening program extension via a plausible bounds approach. Value Health 2010;13:215-21. http://dx.doi.org/10.1111/j.1524-4733.2009.00667.x
45. National Institute for Health and Clinical Excellence (NICE). Familial breast cancer costing report, CG041. London: NICE; 2006.
46. Robertson C, Arcot Ragupathy SK, Boachie C, Dixon JM, Fraser C, Hernández R, et al. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews, registry database analyses and economic evaluation. Health Technol Assess 2011;15(34).
47. Turnbull LW, Brown SR, Olivier C, Harvey I, Brown J, Drew P, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess 2010;14(1).
48. Maurice A, Evans DGR, Shenton A, Ashcroft L, Baildam A, Barr L, et al. Screening younger women with a family history of breast cancer-does early detection improve outcome? Eur J Cancer 2006;42:1385-90. http://dx.doi.org/10.1016/j.ejca.2006.01.055
49. Moss S, Cuckle H, Evans A, Johns L, Waller M, Bobrow L. Effect of mammography screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006;368:2053-60. http://dx.doi.org/10.1016/S0140-6736(06)69834-6
50. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002;359:909-19. http://dx.doi.org/10.1016/S0140-6736(02)08020-0
51. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 2002;137:305-12.
52. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000;92:1490-9. http://dx.doi. org/10.1093/jnci/92.18.1490
53. Tabar L, Vitak B, Chen HH, Duffy SW, Smith RA. The Swedish Two-County Trial twenty years later: updated mortality results and new insights from long term follow-up. Radiol Clin N Amer 2000;38:625-51.
54. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet 1999;353:1903-
55. http://dx.doi.org/10.1016/S0140-6736(98)07413-3
56. Shapiro S, Venet W, Strax P, Venet L. Periodic screening for breast cancer: the health insurance project and its sequelae 1963-86. Baltimore, MD: Johns Hopkins UP; 1988.
57. Pinder SE, Wencyk PM, Naylor HE, Bell JA, Elston CW, Robertson JF, et al. The assessment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: method, preliminary results and prognostic associations. Cytopathol 1995;6:316-24. http://dx.doi. org/10.1111/j.1365-2303.1995.tb00577.x
58. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, et al. Molecular characteristics of screen detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009;101:1338-44. http://dx.doi.org/10.1038/sj.bjc.6605317
59. Lawrence G, O'Sullivan E, Kearins O, Tappenden N, Martin K, Wallis M, et al. Screening histories of invasive breast cancers diagnosed 1989-2006 in the West Midlands, UK: variation with time and impact on survival. J Med Screen 2009;16:186-92. http://dx.doi.org/10.1258/jms.2009.009040
60. Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, et al. Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 2011;117:1360-8. http://dx.doi.org/10.1002/cncr.25613
61. Wallis MG, Clements K, Kearins O, Ball G, Mccartney J, Lawrence GM. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 2012;106:1611-17. http://dx.doi.org/10.1038/bjc.2012.151
62. Norman RP, Evans DG, Easton DF, Young KC. The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur J Health Econ 2007;8:137-44. http:// dx.doi.org/10.1007/s10198-007-0042-9
63. Evans AJ, Kutt E, Record C, Waller M, Moss S. Radiological findings of screen-detected cancers in a multi-centre randomized controlled trial of mammographic screening in women from age 40 to 48 years. Clin Radiol 2006;61:784-8. http://dx.doi.org/10.1016/j.crad.2006.04.013
64. Warren RM, Young JR, McLean L, Lyons K, Wilson AR, Evans A, et al. Radiology review of the UKCCCR Breast Screening Frequency Trial: potential improvements in sensitivity and lead time of radiological signs. Clin Radiol 2003;58:128-32. http://dx.doi.org/10.1053/crad.2002.1132
65. Gilbert FJ, Warren R, Kwan-Lim G, Thompson DJ, Eeles RA, Evans DG, et al. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. Radiology 2009;252:358-68. http://dx.doi.org/10.1148/radiol.2522081032
66. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG. Prospective study of outcomes in sporadic and hereditary breast cancer (POSH): study protocol. Cancer 2007;7:160.
67. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006,15:1159-69. http://dx.doi. org/10.1158/1055-9965.EPI-06-0034
68. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007,356:227-36. http://dx.doi.org/10.1056/ NEJMoa062790
69. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade III invasive ductal carcinoma of the breast. Histopathology 2006;49:22-34. http://dx.doi.org/10.1111/j.1365-2559.2006.02453.x
70. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52. http://dx.doi.org/10.1038/35021093
71. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10,869-74. http://dx.doi.org/10.1073/pnas.191367098
72. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and the basal epithelial phenotype. J Natl Cancer Inst 2003;99:1482-5. http://dx.doi. org/10.1093/jnci/djg050
73. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal like breast cancer. Breast Cancer Res Treat 2008;109:123-39. http://dx.doi.org/10.1007/ s10549-007-9632-6
74. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction is sporadic basal-like breast cancer. Oncogene 2007;26:2126-32. http://dx.doi.org/10.1038/ sj.onc.1210014
75. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci USA 2003;100:10,393-8. http://dx.doi.org/10.1073/pnas.1732912100
76. Teschendorff AE, Journée M, Absil PA, Sepulchre R, Caldas C. Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comp Biol 2007;3:e161. http://dx.doi.org/10.1371/journal.pcbi.0030161
77. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15. http://dx.doi.org/10.1158/0008-5472.CAN-06-0140
78. House W, Sharp D, Sheridan E. Identifying and screening patients at high risk of colorectal cancer in general practice. J Med Screen 1999;6:205-8.
79. Schrijvers CT, Stronks K, van de Mheen DH, Coebergh JW, Mackenbach JP. Validation of cancer prevalence data from a postal survey by comparison with cancer registry records. Am J Epidemiol 1994;139:408-14.
80. Clements A, Henderson B, Tyndel S, Evans G, Brain K, Austoker J, et al. Diagnosed with breast cancer while on a family history screening programme: an exploratory qualitative study. Eur J Cancer Care 2008;17:245-52. http://dx.doi.org/10.1111/j.1365-2354.2007.00837.x
81. Duffy SW, Tabar L, Olsen AH, Vitak B, Allgood PC, Chen TH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screening 2010;17:25-30. http://dx.doi.org/10.1258/ jms.2009.009094
82. Stone J, Ding J, Warren RM, Duffy SW. Predicting breast cancer risk using mammographic density measurements from both mammogram sides and views. Breast Cancer Res Treat 2010;124:551-4. http://dx.doi.org/10.1007/s10549-010-0976-y
83. Aarøe J, Lindahl T, Dumeaux V, Saebø S, Tobin D, Hagen N, et al. Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res 2010;12:R7. http:// dx.doi.org/10.1186/bcr2472
84. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007;18:868-73. http://dx.doi. org/10.1093/annonc/mdm007
85. Rønneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, et al. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 2011;5:61-76. http://dx.doi. org/10.1016/j.molonc.2010.11.004
86. Hologic. Understanding R2 Quantra 1.3. Bedford, MA: Hologic Inc.; 2009.
87. UK National Statistics. URL: www.statistics.gov.uk/ (accessed 26 November 2012).
88. Scheuner MT, McNeel TS, Freedman AN. Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey. Genet Med 2010;12:726-35. http://dx.doi.org/10.1097/GIM.0b013e3181f30e9e
89. O'Neill SM, Rubinstein WS, Wang C, Yoon PW, Acheson LS, Rothrock N, et al. Familial risk for common diseases in primary care: the Family Healthware Impact Trial. Am J Prev Med 2009;36:506-14. http://dx.doi.org/10.1016/j.amepre.2009.03.002
90. Stone J, Ding J, Warren RM, Duffy SW, Hopper JL. Using mammographic density to predict breast cancer risk: dense area or percentage dense area. Breast Cancer Res 2010;12:R97. http://dx.doi. org/10.1186/bcr2778
91. Wong CS, Lim GH, Gao F, Jakes RW, Offman J, Chia KS, et al. Mammographic density and its interaction with other breast cancer risk factors in an Asian population. Br J Cancer 2011;104:871-4. http://dx.doi.org/10.1038/sj.bjc.6606085